全文获取类型
收费全文 | 9780篇 |
免费 | 581篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 306篇 |
妇产科学 | 118篇 |
基础医学 | 1158篇 |
口腔科学 | 441篇 |
临床医学 | 870篇 |
内科学 | 2332篇 |
皮肤病学 | 231篇 |
神经病学 | 789篇 |
特种医学 | 462篇 |
外科学 | 1623篇 |
综合类 | 18篇 |
一般理论 | 1篇 |
预防医学 | 500篇 |
眼科学 | 93篇 |
药学 | 449篇 |
中国医学 | 11篇 |
肿瘤学 | 964篇 |
出版年
2023年 | 123篇 |
2022年 | 94篇 |
2021年 | 391篇 |
2020年 | 208篇 |
2019年 | 329篇 |
2018年 | 402篇 |
2017年 | 265篇 |
2016年 | 268篇 |
2015年 | 302篇 |
2014年 | 393篇 |
2013年 | 464篇 |
2012年 | 669篇 |
2011年 | 732篇 |
2010年 | 426篇 |
2009年 | 396篇 |
2008年 | 616篇 |
2007年 | 597篇 |
2006年 | 569篇 |
2005年 | 560篇 |
2004年 | 507篇 |
2003年 | 454篇 |
2002年 | 370篇 |
2001年 | 171篇 |
2000年 | 140篇 |
1999年 | 121篇 |
1998年 | 56篇 |
1997年 | 60篇 |
1996年 | 48篇 |
1995年 | 44篇 |
1994年 | 39篇 |
1993年 | 38篇 |
1992年 | 59篇 |
1991年 | 47篇 |
1990年 | 49篇 |
1989年 | 43篇 |
1988年 | 42篇 |
1987年 | 36篇 |
1986年 | 35篇 |
1985年 | 29篇 |
1984年 | 23篇 |
1983年 | 23篇 |
1982年 | 19篇 |
1980年 | 15篇 |
1979年 | 19篇 |
1978年 | 12篇 |
1977年 | 18篇 |
1975年 | 15篇 |
1974年 | 13篇 |
1973年 | 14篇 |
1968年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
1.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献
2.
3.
4.
5.
Andrea Garatti Andrea Daprati Marzia Cottini Claudio F. Russo Margherita Dalla Tomba Giovanni Troise Antonio Salsano Francesco Santini Roberto Scrofani Francesca Nicolò Elisa Mikus Alberto Albertini Luca Di Marco Davide Pacini Marco Picichè Loris Salvador Guglielmo M. Actis Dato Paolo Centofanti Lorenzo Menicanti 《The Annals of thoracic surgery》2021,111(4):1242-1251
6.
Lorenzo Alibardi 《Developmental dynamics》2022,251(9):1404-1413
An evolutionary hypothesis explaining failure of regeneration among vertebrates is presented. Regeneration derives from postembryonic processes present during the life cycles of fish and amphibians that include larval and metamorphic phases with broad organ reorganizations. Developmental programs imprinted in their genomes are re-utilized with variations also in adults for regeneration. When vertebrates colonized land adopting the amniotic egg, some genes driving larval changes, and metamorphosis were lost and new genes evolved, further limiting regeneration. These included neural inhibitors for maintaining complex nervous systems, behavior and various levels of intelligence, and adaptive immune cells. The latter, that in anamniotes are executioners of metamorphic reorganization, became intolerant to embryonic-oncofetal-antigens impeding organ regeneration, a process that requires de-differentiation of adult cells and/or expansion of stem cells where these early antigens are formed. The evolution of terrestrial lifecycles produced vertebrates with complex bodies but no longer capable to regenerate their organs, mainly repaired by regengrow. Efforts of regenerative medicine to improve healing in humans should determine the diverse developmental pathways evolved between anamniotes and amniotes before attempting genetic manipulations such as the introduction of “anamniote regenerative genes” in amniotes. This operation may determine alteration in amniote developmental programs leading to teratomes, cancer, or death. 相似文献
7.
Rosario Mazzola Giulio Francolini Luca Triggiani Giuseppe Napoli Francesco Cuccia Luca Nicosia Lorenzo Livi Stefano Maria Magrini Matteo Salgarello Filippo Alongi 《Clinical genitourinary cancer》2021,19(3):230-236
BackgroundThe present analysis aims to compare the impact of 18F-fluorocholine (18F-choline) and gallium-68 prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography (PET)-computed tomography (CT)–guided metastases-directed therapies (MDTs) in patients with castration-sensitive oligorecurrent prostate cancer (PC).Materials and MethodsInclusion criteria were: (1) histologically proven prostate adenocarcinoma; (2) evidence of biochemical relapse after primary tumor treatment; (3) ≤ 3 hypermetabolic oligorecurrent lesions detected by 18F-choline or 68Ga-PSMA PET-CT; (4) PET-CT imaging performed in a single nuclear medicine department; (5) patients treated with upfront stereotactic body radiotherapy (SBRT) without hormone therapy; and (6) SBRT delivered with a dose per fraction ≥ 5 Gy. In the case of oligoprogression (≤ 3 lesions outside the previous RT field) after MTD, a further course of SBRT was proposed; otherwise, androgen deprivation therapy (ADT) was administered.ResultsA total of 118 lesions in 88 patients were analyzed. Forty-four (50%) patients underwent 68Ga-PSMA PET-guided SBRT, and the remaining underwent choline PET-based SBRT. The median follow-up was 25 months (range, 5-87 months) for the entire cohort. Overall survival and local control were both 100%. Distant progression occurred in 48 (54.5%) patients, for a median distant progression-free survival of 22.8 months (range, 14.4-28.8 months). The median pre-SBRT prostate-specific antigen was 2.04 ng/mL in the choline PET cohort and 0.58 ng/mL in the PSMA-PET arm. Disease-free survival rates were 63.6% and 34%, respectively, in the 68Ga-PSMA and choline PET group (P = .06). The ADT administration rate was higher after choline-PET–guided SBRT (P = .00) owing to the higher incidence of polymetastatic disease after first-course SBRT compared with 68Ga-PSMA-based SBRT.ConclusionIn the setting of oligorecurrent castration-sensitive PC, PSMA-PET-guided SBRT produced a higher rate of ADT-free patients when compared with the 18F-choline-PET cohort. Randomized trials are advocated. 相似文献
8.
Noreen M. Walsh Heinz Kutzner Luis Requena Lorenzo Cerroni 《Journal of cutaneous pathology》2019,46(9):698-708
We review the spectrum of cutaneous disorders associated with inflammatory and neoplastic plasmacytic pathology. Because plasma cells are derived from B‐lymphocytes our overview includes discussion of certain lymphoplasmacytic proliferations. It is structured along histopathological lines, addressing conditions characterized by (a) cutaneous plasma cell infiltrates, (b) deposits of plasma cell products or their derivatives in the skin and (c) miscellaneous, poorly understood cutaneous complications of plasmacytic disorders. Lesions arising primarily in the skin and those due to cutaneous involvement by multisystem disorders are addressed. The range includes a spectrum of tumefactive and circulatory manifestations. We highlight key clinical and pathological features of the different conditions and outline recent advances in our understanding of these entities. By emphasizing the dermatopathological characteristics of this spectrum of disorders we hope to hone the diagnostic accuracy of practitioners in the field. 相似文献
9.
10.
Segui M. A. Cruz J. J. Alba E. Feliu J. Jara C. Rivera F. Rodriguez Lescure A. Lorenzo A. Martin M. 《Clinical & translational oncology》2020,22(7):1049-1058
Clinical and Translational Oncology - The Spanish Society of Medical Oncology (SEOM, for its Spanish acronym) would like to attest to the relevance of training in Oncology as part of the... 相似文献